AMGEN INC (AMG.DE) Stock Price, Quote, News and Overview
FRA:AMG - Deutsche Boerse Ag - US0311621009 - Common Stock - Currency: EUR
AMG.DE Quote, Performance and Key Statistics
AMGEN INC
FRA:AMG (2/4/2025, 7:00:00 PM)
278.25
-1.95 (-0.7%)
The current stock price of AMG.DE is 278.25 EUR. In the past month the price increased by 10.24%. In the past year, price increased by 3.21%.
AMG.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 18.69 | 323.32B | ||
| 1AMGN.MI | AMGEN INC | 14.81 | 148.09B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 937.76 | 118.34B | ||
| GIS.DE | GILEAD SCIENCES INC | 21.97 | 117.44B | ||
| ARGX.BR | ARGENX SE | N/A | 37.64B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 27.07B | ||
| IDP.DE | BIOGEN INC | 8.75 | 20.15B | ||
| 0QF.DE | MODERNA INC | N/A | 13.30B | ||
| 1MRNA.MI | MODERNA INC | N/A | 13.08B | ||
| ALEMS.BR | EUROPEAN MEDICAL SOLUTIONS S | N/A | 9.95B | ||
| GLPG.AS | GALAPAGOS NV | 7 | 1.44B | ||
| NVV1.DE | NOVAVAX INC | N/A | 1.30B |
Related stock screener links
About AMG.DE
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 26,700 full-time employees. The firm discovers, develops, manufactures and delivers various human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. The company operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.
Company Info
AMGEN INC
One Amgen Center Drive
Thousand Oaks CALIFORNIA US
Employees: 26700
Company Website: https://www.amgen.com/
Investor Relations: https://investors.amgen.com
Phone: 18054471000
AMG.DE FAQ
What is the stock price of AMG.DE?
The current stock price of AMG.DE is 278.25 EUR.
What is the symbol for AMGEN INC stock?
The exchange symbol of AMGEN INC is AMG and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is AMG.DE stock listed?
AMG.DE stock is listed on the Deutsche Boerse Ag exchange.
Is AMG.DE a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for AMG.DE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of AMG.DE.
Does AMG.DE stock pay dividends?
AMG.DE has a dividend yield of 3.35%. The yearly dividend amount is currently 8.52.
When does AMG.DE stock report earnings?
AMG.DE will report earnings on 2025-02-04, after the market close.
What is the Price/Earnings (PE) ratio of AMG.DE?
The PE ratio for AMG.DE is 14.96. This is based on the reported non-GAAP earnings per share of 18.6 and the current share price of 278.25 EUR.
AMG.DE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to AMG.DE. When comparing the yearly performance of all stocks, AMG.DE is a bad performer in the overall market: 80.5% of all stocks are doing better.
AMG.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AMG.DE. While AMG.DE belongs to the best of the industry regarding profitability, there are concerns on its financial health.
AMG.DE Financial Highlights
Over the last trailing twelve months AMG.DE reported a non-GAAP Earnings per Share(EPS) of 18.6. The EPS increased by 6.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13% | ||
| ROA | 4.65% | ||
| ROE | 56.2% | ||
| Debt/Equity | 7.55 |
AMG.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to AMG.DE. The Buy consensus is the average rating of analysts ratings from 39 analysts.
For the next year, analysts expect an EPS growth of 7.12% and a revenue growth 17.88% for AMG.DE